| Gene symbol | MAGEA10 | Synonyms | CT1.10, MAGE10 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | MAGE family member A10 | ||||
| GTO ID | GTC0274 |
| Trial ID | NCT02592577 |
| Disease | Lung Non-Small Cell Carcinoma | Carcinoma |
| Altered gene | MAGE-A10 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | ADP-A2M10 |
| HLA | HLA-A*02:01|HLA-A*02:06 |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10c796 T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) |
| Year | 2015 |
| Country | United States |
| Company sponsor | Adaptimmune |
| Other ID(s) | ADP 0022-003 |
| Vector information | |||||
|
|||||
| Cohort 1 | |||||||||||||||||||
|
|||||||||||||||||||